



EVITRADE Names Renowned Cannabinologist Dr. Ricardo E Rivera-Acevedo to Scientific Advisory Board

VANCOUVER, BC, Friday February 8, 2019 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the “Company”) announces that it appointed Dr. Rivera-Acevedo to its Scientific Advisory Board.

Dr. Ricardo E Rivera-Acevedo is an Adjunct Professor in the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia. Dr. Rivera-Acevedo brings extensive industry and academic drug development expertise. He earned a BSc from the University of Puerto Rico, as well as PhD and Postdoctoral work from UBC, prior to branching off into the biotech industry. He helped start two cannabis research companies, Canalytic Laboratories and Cannevert Therapeutics Ltd. In 2015, Ricardo established the first analytical laboratory for cannabinoid research in the Department of Pharmacology at UBC, which is dedicated to understanding the therapeutic implications of specific cannabis strains and formulations to treat different diseases. As the youngest faculty member within the Department of Pharmacology, Ricardo teaches various undergraduate courses including Drug Development, Natural Health Products, and Pharmacogenomics. He’s led research teams conducting R&D, QA/QC, and manufacturing research to improve formulations from cannabis extracted cannabinoids. He helped to organize and supervise one of the first internationally recognized clinical trials with cannabis in Puerto Rico testing the analgesic properties of a promising new cannabis cultivar. Dr. Rivera-Acevedo’s expertise is now being transmitted globally as co-host on the Cannabis Science Podcast, show belonging to the Vancouver Coop Radio online channel.

“I am pleased to join the Evitrade Health Group and am looking forward to advising and working with the technologies that the company has to help improve patient health systems” said Dr. Rivera-Acevedo.

“We are fortunate to have someone with Dr. Rivera-Acevedo’s knowledge and experiences as scientific advisor for this company” said CEO C.K. Cheung, “With his proven track record we expect that he will be a critical asset to help us successfully implement and take advantage of the numerous market opportunities that we have in front of us.”

Management continues to strive to seek optimal business and commercialization strategies for the Company and welcomes Dr. Ricardo Rivera-Acevedo to the Company.

Contact:

C.K. Cheung, CEO, Director

EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com or ceo@auxellence.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp> US OTC Markets

(OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

About EVITRADE Health (CSE: EVA, OTCQB: EVAHF)



EVITRADE Health Systems Corp. (formerly Auxellence Health Corp.), is a Technology company specializing in the Life Sciences sector looking to deliver effective health solutions with a higher degree of predictability and consistency. The Company is focused in four main areas, Autonomous Medical Care, Molecular Biology, Nutraceutical Solutions and Genetic Selection. Through its Focus on Autonomous Medical Care, the Company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.

Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcmarkets.com/stock/EVAHF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.